Technical cookies are required for the site to function properly, to be legally compliant and secure. Session cookies only last for the duration of your visit and are deleted from your device when you close your internet browser. Persistent cookies, however, remain and continue functioning on repeat visits.
Personalisation cookies collect information about your website browsing habits and offer you a personalised user experience based on past visits, your location or browser settings. They also allow you to log in to personalised areas and to access third party tools that may be embedded in our website. Some functionality will not work if you don’t accept these cookies.
Immatics N.V. has announced the completion of its business combination with Arya Sciences Acquisition Corporation. The Immatics shares and warrants are now traded under the symbol “IMTX” and the symbol “IMTXW” on the Nasdaq Capital Market.
The proceeds from this transaction were approximately $253 million, which included funds held in Arya’s trust account and the common stock private investment in public equity (PIPE) financing contributed by a group of leading US healthcare institutional investors.
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies. Arya Sciences Acquisition Corporation is a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. Immatics’ management team, led by CEO Harpreet Singh, Ph.D., will continue to run the combined company.
An international CMS team supported Immatics on all legal aspects of the transaction in the Netherlands and Germany. The Dutch team was led by Martijn van der Bie and Clair Wermers and the German team by Stefan-Ulrich Müller and Tilman Weichert.